Medtas Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -31.28%
- Profit Growth -15.50%
- Ebitda -57.01%
- Net Worth 39.68%
- Total Assets 144.27%
About Medtas Pharmaceuticals
Medtas Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 30 September 2014 and has a history of Ten years and four months. Its registered office is in Sant Kabir Nagar, Uttar Pradesh, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ravi Pushpjivi and Veerendra Kumar serve as directors at the Company.
Company Details
- Location
Sant Kabir Nagar, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74120UP2014PTC066348
- Company No.
066348
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Medtas Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Pushpjivi  | Director | 30-Sep-2014 | Current |
| Veerendra Kumar | Director | 30-Sep-2014 | Current |
Financial Performance of Medtas Pharmaceuticals.
Medtas Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 31.28% decrease. The company also saw a substantial fall in profitability, with a 15.5% decrease in profit. The company's net worth Soared by an impressive increase of 39.68%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medtas Pharmaceuticals?
In 2017, Medtas Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aksmed Healthcare Private LimitedRavi Pushpjivi is a mutual person
- Mensun Pharmaceuticals Private Limited
Veerendra Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medtas Pharmaceuticals?
Unlock and access historical data on people associated with Medtas Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medtas Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medtas Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.